| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000023354 |
| Receipt No. | R000026702 |
| Official scientific title of the study | Effects of Bifidobacterium breve (BBG-01) administration in Neonatal Intensive Care Unit cared preterm infants to gain enterobacterial flora |
| Date of disclosure of the study information | 2016/08/15 |
| Last modified on | 2016/07/27 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effects of Bifidobacterium breve (BBG-01) administration in Neonatal Intensive Care Unit cared preterm infants to gain enterobacterial flora | |
| Title of the study (Brief title) | Effects of Bifidobacterium breve (BBG-01) administration in Neonatal Intensive Care Unit cared preterm infants | |
| Region |
|
|
| Condition | ||
| Condition | Neonatal Intensive Care Unit cared preterm infants | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We will evaluate the effects of B. breve administration for early development of bifidobacteria dominated microbiota in Neonatal Intensive Care Unit cared preterm infants. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Early development of bifidobacteria dominated microbiota |
| Key secondary outcomes | Weight gain, diseases prevention, and infants' health |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -but assessor(s) are blinded |
| Control | No treatment |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | BBG-01 | |
| Interventions/Control_2 | BBG-01 | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | BBG-01 | |||
| Key exclusion criteria | BBG-01 | |||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Hisamichi Tauchi |
| Organization | Ehime University Graduate School of Medicine |
| Division name | Department of Pediatrics |
| Address | Shitsukawa, Toon, Ehime |
| TEL | 089-960-5320 |
| tauchi@m.ehime-u.ac.jp | |
| Public contact | |
| Name of contact person | Hisamichi Tauchi |
| Organization | Ehime University Graduate School of Medicine |
| Division name | Department of Pediatrics |
| Address | Shitsukawa, Toon, Ehime |
| TEL | 089-960-5320 |
| Homepage URL | |
| tauchi@m.ehime-u.ac.jp | |
| Sponsor | |
| Institute | Ehime University Graduate School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Ehime University Graduate School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026702 |